Cardiome definition

Cardiome has the meaning set forth in Section 16.1.
Sample 1Sample 2Sample 3
Cardiome means Cardiome Pharma Corp., a corporation existing under the federal laws of Canada;
Sample 1Sample 2
Cardiome means Cardiome Pharma Corp.
Sample 1

Examples of Cardiome in a sentence

  • I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of Cardiome Pharma Corp.

  • Principles of consolidation: The consolidated financial statements include the accounts of Cardiome Pharma Corp.

  • Principles of consolidation: These consolidated financial statements include the accounts of Cardiome Pharma Corp.

  • I have reviewed the interim filings (as this term is defined in Multilateral Instrument 52- 109 Certification of Disclosure in Issuers’ Annual and Interim Filings) of Cardiome Pharma Corp.

  • I have reviewed the interim filings (as this term is defined in Multilateral Instrument 52-109 Certification of Disclosure in Issuers’ Annual and Interim Filings) of Cardiome Pharma Corp.

  • On the history of privacy certificates see Madden and Lessin, supra note 81, p.263, and R.T. Nelson andT.E Hedrick, "The Statutory Protection of Confidential Research Data: Synthesis and Evaluation" (at p.213) In Boruch and Cecil, supra note 14.state — they offer impressive protections.

  • Cardiome’s management team and employees became employees of the Company and assumed the same positions they occupied in Cardiome.

  • Immediately following the reorganization of Cardiome, Cipher Pharmaceuticals Inc.

  • The consolidated financial statements for all periods presented herein include the consolidated operations of Cardiome until May 15, 2018 and the operations of the Company thereafter.

  • Pursuant to the Arrangement effective May 15, 2018, substantially all of the assets and liabilities of Cardiome excluding its Canadian business portfolio were transferred to Correvio and the shareholders of Cardiome received common shares, on a one-for-one basis, of Correvio.


More Definitions of Cardiome

Cardiome means Cardiome Pharma Corp.; “CBP” means CREB-binding protein; “CEO” means Chief Executive Officer; “CFO” means Chief Financial Officer;
Sample 1
Cardiome or the “Company”), today announced that it has entered into a bought deal agreement with a syndicate of underwriters led by Orion Securities Inc. and Sprott Securities Inc., and including First Associates Investments Inc., Xxxxxxx Xxxxx Ltd., and Research Capital Corporation. Under the agreement, the syndicate has agreed to purchase 3,810,000 common shares (“Common Shares”) at a price of $5.25 per Common Share, resulting in gross proceeds to the Company of $20,002,500. In addition, the underwriters will have the option, exercisable for a period of 30 days after Closing, to acquire up to an aggregate of 571,500 additional Common Shares at the offering price to cover over-allotments, if any. The net proceeds from the offering will be used to fund clinical trials and for general corporate purposes. The offering is expected to close on or about September 23, 2003. The transaction is subject to the receipt of all necessary regulatory and stock exchange approvals. THE COMMON SHARES HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED, AND MAY NOT BE OFFERED OR SOLD WITHIN THE UNITED STATES OR TO, OR FOR THE ACCOUNT OR BENEFIT OF, U.S. PERSONS ABSENT U.S. REGISTRATION OR AN APPLICABLE EXEMPTION FROM U.S. REGISTRATION REQUIREMENTS. About Cardiome Pharma Corp. Cardiome Pharma Corp. is a product-focused cardiovascular drug development company. Cardiome has three late stage clinical drug programs focused on atrial arrhythmias, congestive heart failure, and hyperuricemia (gout). Cardiome’s lead antiarrhythmic product, RSD1235, is an acute-use, intravenous administration treatment for atrial fibrillation (AF). RSD1235 selectively blocks ion channels in the heart that are known to be active during episodes of atrial fibrillation. This unique mechanism of action of RSD1235 combined with supportive preclinical and clinical data suggests that RSD1235 may be able to effectively treat atrial arrhythmia with a high margin of safety. Cardiome’s lead product in the congestive heart failure area is oxypurinol, a novel therapy in treating the disease. Cardiome also plans to develop oxypurinol as a treatment of gout for patients who are intolerant to allopurinol, the first-line therapy for gout. Cardiome is traded on the Toronto Stock Exchange (COM). Further information about Cardiome can be found at: xxx.xxxxxxxx.xxx. ON BEHALF OF THE BOARD “Xxxxxx Xxxxxx” President & Chief Executive Officer For more information:
Sample 1
Cardiome or the “Corporation”) in connection with the issue and sale by the Corporation (the “Offering”) on this date (the “Closing Date”) of an aggregate of [●] common shares in the capital of the Corporation (each, a “Firm Share” and collectively, the “Firm Shares”) at a price of US$[●] per Firm Share, pursuant to the terms of an underwriting agreement (the “Underwriting Agreement”) dated July [●], 2016 among the Corporation and Leerink Partners LLC, [●], [●] and [●] (collectively, the “Underwriters”). Pursuant to the Underwriting Agreement, Cardiome has also granted to the Underwriters an option (the “Option”) to acquire up to an additional [●] common shares (each, an “Option Share” and, collectively, the “Option Shares”, and the Option Shares, together with the Firm Shares, the “Shares”) on the same terms as set forth above. [The Underwriters have exercised the Option in [part/full], by notice to the Corporation dated [●], 2016.] The Shares are being offered and sold pursuant to the Canadian Prospectus Supplement (as defined below) filed with the securities regulatory authority in each of the Provinces of Canada, except Québec and pursuant to the registration statement on Form F-10 (File No. [●]), as amended (the “Registration Statement”) and related US Prospectus Supplement (as defined below) filed with the United States Securities and Exchange Commission. This opinion is being delivered to you pursuant to section 8(b) of the Underwriting Agreement. Capitalized terms used herein which are not otherwise defined herein shall have the meanings ascribed to such terms in the Underwriting Agreement unless the context otherwise requires. As counsel to the Corporation, we, together with Skadden, Arps, Slate, Mxxxxxx & Fxxx LLP (U.S. counsel to the Corporation), the Underwriters, Stikeman Elliott LLP and Lxxxxx & Wxxxxxx LLP (together, counsel to the Underwriters), have reviewed and/or participated in the preparation of the following:
Sample 1

Related to Cardiome

  • IDT means intradepartmental transfer.

  • Sage means The Sage Group plc or an Affiliate thereof.

  • Shire means Shire of Augusta Margaret River

  • Merck has the meaning set forth in the preamble.

  • Novartis shall have the meaning set forth in the Preamble.

  • Siemens means Siemens AG (Germany) and its Affiliates.

  • Lilly has the meaning set forth in the Preamble.

  • Raptor means all birds of the orders Falconiformes and Strigiformes, commonly called falcons,

  • AMS means the Federal Aviation Administration’s Acquisition Management System.

  • BLS means Basic Life Support.

  • Arena means an enclosed building:

  • Spectrum means frequencies of electromagnetic spectrum used to provide fixed or mobile communications services as licensed or authorized by the FCC.

  • TEQ means toxicity equivalence, the international method of relating the toxicity of various dioxin/furan congeners to the toxicity of 2,3,7,8-tetrachlorodibenzo-p-dioxin.

  • CTI means CTI Logistics Limited (ABN 69 008 778 925) and/or any Affiliate of CTI Logistics Limited as the case may be, which performs all or any of the Services.

  • the Licensee means the person(s) named in the licence.

  • Licensee has the meaning set forth in the preamble.

  • Your Products means products developed or to be developed by or for You that include an Intel Component executing the Materials. 2.

  • CIMA means the Cayman Islands Monetary Authority whose contact details are available from www.cima.ky;

  • Bioassay means the determination of kinds, quantities or concentrations and, in some cases, the locations of radioactive material in the human body, whether by direct measurement, in vivo counting, or by analysis and evaluation of materials excreted or removed from the human body. For purposes of these rules, “radiobioassay” is an equivalent term.

  • BMS means the Company, all related companies, affiliates, subsidiaries, parents, successors, assigns and all organizations acquired by the foregoing.

  • Modern biotechnology means the application of:

  • DSM means the most current edition of the Diagnostic and Statistical Manual of Mental Disorders published by the American Psychiatric Association.

  • VET means vocational education and training.

  • EMD means Earnest Money Deposit.

  • Intel means Intel Corporation, a Delaware corporation.

  • OMP means Occupational Medical Practitioner